Abstract
The insulin-like growth factor I receptor (IGF-IR) pathway plays a major role in cancer growth, tumor cell survival and resistance to therapy. Ancillary evidence that targeting the IGF-IR may be useful in the treatment of cancer has been accumulating for almost two decades. Today, more than two dozen compounds have been developed and clinical trials are underway for at least 12 of those. The ability to pharmacologically control the IGF-IR pathway holds not only promising therapeutic implications but also the possibility to gather a better understanding of the role of the IGF axis in tumor initiation and progression. This review focuses on the preclinical rationale for targeting the IGF-IR and other components of the IGF-I system, early clinical results observed to date, biomarker approaches employed and the lessons from these early results for future study design. Early clinical trials reveal an acceptable safety profile together with pharmacodynamic evidence of receptor targeting. Instances of single-agent activity during phase I evaluations have been well documented and a recently reported randomized phase II study indicates that co-administration of an anti-IGF-IR antibody with chemotherapy improves objective response rate and progression-free survival in non-small cell lung cancer patients. These early results support ongoing research across a broad range of cancer indications.
Keywords: A12, cixutumumab, AMG-479, AVE1642, AXL1717, BIIB022, BMS-754807, CP-751,871, figitumumab, MK0646
Current Drug Targets
Title: Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
Volume: 10 Issue: 10
Author(s): Antonio Gualberto and Michael Pollak
Affiliation:
Keywords: A12, cixutumumab, AMG-479, AVE1642, AXL1717, BIIB022, BMS-754807, CP-751,871, figitumumab, MK0646
Abstract: The insulin-like growth factor I receptor (IGF-IR) pathway plays a major role in cancer growth, tumor cell survival and resistance to therapy. Ancillary evidence that targeting the IGF-IR may be useful in the treatment of cancer has been accumulating for almost two decades. Today, more than two dozen compounds have been developed and clinical trials are underway for at least 12 of those. The ability to pharmacologically control the IGF-IR pathway holds not only promising therapeutic implications but also the possibility to gather a better understanding of the role of the IGF axis in tumor initiation and progression. This review focuses on the preclinical rationale for targeting the IGF-IR and other components of the IGF-I system, early clinical results observed to date, biomarker approaches employed and the lessons from these early results for future study design. Early clinical trials reveal an acceptable safety profile together with pharmacodynamic evidence of receptor targeting. Instances of single-agent activity during phase I evaluations have been well documented and a recently reported randomized phase II study indicates that co-administration of an anti-IGF-IR antibody with chemotherapy improves objective response rate and progression-free survival in non-small cell lung cancer patients. These early results support ongoing research across a broad range of cancer indications.
Export Options
About this article
Cite this article as:
Gualberto Antonio and Pollak Michael, Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology, Current Drug Targets 2009; 10 (10) . https://dx.doi.org/10.2174/138945009789577945
DOI https://dx.doi.org/10.2174/138945009789577945 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Radiosyntheses using Fluorine-18: The Art and Science of Late Stage Fluorination
Current Topics in Medicinal Chemistry Non Smoking for Successful Aging: Therapeutic Perspectives
Current Pharmaceutical Design 9-Hydroxyellipticine and Derivatives as Chemotherapy Agents
Mini-Reviews in Medicinal Chemistry The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry MicroRNAs and the Warburg Effect: New Players in an Old Arena
Current Gene Therapy Avian Cytokines - An Overview
Current Pharmaceutical Design Therapeutic Perspectives on Pancreatic Cancer
Current Cancer Drug Targets Chaperoning the Cancer: The Proteostatic Functions of the Heat Shock Proteins in Cancer
Recent Patents on Anti-Cancer Drug Discovery Bone Metastasis-Related MicroRNAs: New Targets for Treatment?
Current Cancer Drug Targets Recent Mass Spectrometric Based Methods in Quantitative N-linked Glycoproteomics
Current Proteomics Investigation of <i>ACE rs4646994, MTHFR rs1801133</i> and <i>VDR rs2228570</i> Genotypes in Jordanian Patients with Fibromyalgia Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Bisphosphonates as Treatment of Bone Metastases
Current Pharmaceutical Design Spinacia oleracea Linn Considered as One of the Most Perfect Foods: A Pharmacological and Phytochemical Review
Mini-Reviews in Medicinal Chemistry Editorial (Hot Topic Potential Value and Limitation of Dual Inhibitors of PI3K and mTOR in the Treatment of Cancer)
Current Cancer Drug Targets EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer
Recent Patents on Anti-Cancer Drug Discovery Regulation of Cell Death and Survival by Resveratrol: Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers
Current Drug Targets What Makes Y Family Pols Potential Candidates for Molecular Targeted Therapies and Novel Biotechnological Applications
Current Molecular Medicine E2F1-Mediated Apoptosis as a Target of Cancer Therapy
Current Molecular Pharmacology